During the study, 24 people travelled to Mount Everest and
underwent assessments of glucose control,
body weight changes and inflammation biomarkers at Everest Base Camp, which is at an altitude of 5,300 m. Half the group remained at Base Camp while the other half climbed the mountain to a maximum of 8,848 m.
Measurements were taken in each group at week six and week eight of the trek.